Increased Levels of TNF-α, IL-6, and IL-10 are Associated with The Degree of Liver Fibrosis in Chronic Hepatitis B Patients with NUC Therapy

Ummi Maimunah, Ulfa Kholili, Rheza Rahmadika Putra, Dio Brimantyo, Hendy Wirantara


BACKGROUND: Liver fibrosis in chronic hepatitis B (CHB) involves the host immune responses mainly T-lymphocyte regulatory cells and cytokines production. Tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-10 have been reported to play a crucial role in the development of liver fibrosis. However, their association with liver fibrosis in treated CHB patients remains unclear. Therefore, this study was conducted to investigate the association between TNF-α, IL-6, and IL-10 with the degree of liver fibrosis in treated CHB patients.

METHODS: This was a cross-sectional prospective study including 101 treated chronic hepatitis B subjects. TNF-α, IL-6, and IL-10 serum levels were measured with quantitative sandwich enzyme-linked immunosorbent assay (ELISA) kit. Transient elastography result was classified according to METAVIR score. Data was analyzed by the Spearman correlation test with a p<0.05 was considered statistically significant.

RESULTS: From 101 subjects, there were significant differences were seen in TNF-α, IL-6, and IL-10 between patients with mild, significant and advance fibrosis. TNF-α (r=0.292; p<0.05), IL-6 (r=0.221; p<0.05), and IL-10 (r=0.208; p<0.05) were significantly correlated with the degree of fibrosis. After multivariate analysis, TNF-α was the only one cytokine parameter which significantly correlated with the degree of fibrosis.

CONCLUSION: Levels of TNF-α, IL-6 and IL-10 are associated with the degree of liver fibrosis. These parameters may potentially be used to evaluate the development of liver fibrosis in treated CHB patients.

KEYWORDS: chronic hepatitis B, liver fibrosis, cytokines, transient elastography

Full Text:



Elbrolosy AN, Elabd NS, ElGedawy GA, Abozeid M, Abdelkreem M, Montaser B, et al. Toll-like receptor 2 polymorphism and IL-6 profile in relation to disease progression in chronic HBV infection: A case control study in Egyptian patients. Clin Exp Med. 2023; 23(1): 117-29, CrossRef.

Muljono DH. Epidemiology of hepatitis B and C in Republic of Indonesia. Euroasian J Hepato-Gastroenterology. 2017; 7(1): 55-9, CrossRef.

Christian JE, Yuliawuri H, Suherman EA. CRISPR target-based single-guide RNA (sgRNA) for diagnostic testing of hepatitis B virus. Mol Cell Biomed Sci. 2023; 7(2): 70-4, CrossRef.

Fatmawati, Nasrul E, Zubir N, Sandra F. Programmed cell death protein 1-overexpressed CD8+ T lymphocytes play a role in increasing chronic hepatitis B disease progression. Indones Biomed J. 2021; 13(3): 310-5, CrossRef.

Sun M, Kisseleva T. Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol. 2015; 39(1): S60-3, CrossRef.

Rockey DC. Liver fibrosis reversion after suppression of hepatitis B virus. Clin Liver Dis. 2016; 20(4): 667-79, CrossRef.

Kang J, Lee M. Noninvasive diagnostic and prognostic assessment tools for liver fibrosis and cirrhosis in patients with chronic liver disease. In: Tsoulfas G, editor. Liver Cirrhosis - Update and Current Challenges. London: IntechOpen; 2017. p.35–75, CrossRef.

Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017; 5(3): 40, CrossRef.

Cheng JYK, Wong GLH. Advances in the diagnosis and treatment of liver fibrosis. Hepatoma Res. 2017; 3(8): 156-69, CrossRef.

Ferraioli G, Wong VWS, Castera L, Berzigotti A, Sporea I, Dietrich CF, et al. Liver ultrasound elastography: An update to the World Federation for Ultrasound in Medicine and Biology guidelines and recommendations. Ultrasound Med Biol. 2018; 44(12): 2419-40, CrossRef.

Chang PE, Goh GBB, Ngu JH, Tan HK, Tan CK. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World J Gastrointest Pharmacol Ther. 2016; 7(1): 91-106, CrossRef.

Mourtzikou A, Alepaki M, Stamouli M, Pouliakis A, Skliris A, Karakitsos P. Evaluation of serum levels of IL-6, TNF-α, IL-10, IL-2 and IL-4 in patients with chronic hepatitis. Inmunología. 2014; 33(2): 41-50, CrossRef.

Ming DS, Lin ZZ, Qiu XD. Analysis of IL-6, IL-10, IL-17 levels in the blood of patients with chronic hepatitis B. Int J Clin Exp Med. 2016; 9(6): 9437-42, article.

Lan T, Chang L, Wu L, Yuan YF. IL-6 plays a crucial role in HBV infection. J Clin Transl Hepatol. 2015; 3(4): 271-6, CrossRef.

de Lédinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterol Clin Biol. 2008; 32(6): 58-67, CrossRef.

Mondelli MU, Varchetta S, Oliviero B. Natural killer cells in viral hepatitis: Facts and controversies. Eur J Clin Invest. 2010; 40(9): 851-63, CrossRef.

Bertoletti A, Maini MK and Ferrari C. The host pathogen interaction during HBV infection: Immunological controversies. Antivir Ther 2010; 15(Suppl3): 15-24, CrossRef.

Chen Z, O’Shea JJ. Th 17 cells: A new fate for differentiating helper T cells. Immunol Res 2008; 41(2): 87-102, CrossRef.

Murata K, Tsukuda S, Suizu F, Kimura A, Sugiyama M, Watashi K, et al. Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection. Hepatology. 2020; 71(5): 1533-45, CrossRef.

Poovorawan K, Tangkijvanich P, Chirathaworn C, Wisedopas N, Treeprasertsuk S, Komolmit P, et al. Circulating cytokines and histological liver damage in chronic hepatitis B infection. Hepat Res Treat. 2013; 2013: 757246, CrossRef.

Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. J Am Acad Dermatol. 2012; 67(6): 1349-61, CrossRef.

Yao QY, Feng YD, Han P, Yang F, Song GQ. Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients. World J Gastroenterol. 2020; 26(27): 3917-28, CrossRef.

Deng YQ, Zhao H, Ma AL, Zhou JY, Xie SB, Zhang XQ, et al. Selected cytokines serve as potential biomarkers for predicting liver inflammation and fibrosis in chronic hepatitis B patients with normal to mildly elevated aminotransferases. Medicine. 2015; 94(45): e2003, CrossRef.

Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011; 25(2): 195-206, CrossRef.

Liu C, Chen X, Yang L, Kisseleva T, Brenner DA, Seki E. Transcriptional repression of the transforming growth factor β (TGF-β) pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) by Nuclear Factor κB (NF-κB) p50 enhances TGF-β signaling in hepatic stellate cells. J Biol Chem. 2014; 289(10): 7082-91, CrossRef.

Tarrats N, Moles A, Morales A, García-Ruiz C, Fernández-Checa JC, Marí M. Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis. Hepatology. 2011; 54(1): 319-27, CrossRef.

Ramakers BP, de Goeij M, van der Hoeven JG, Peters WH, Pickkers P. Inflammation-induced hepatotoxicity in humans. Shock. 2009; 31(2): 151-6, CrossRef.

Wen XY, Xiang CY, Yuan YR. Change of serum TNF-α, IL-6, IL-8, IL-12 and IL-18 in patients with hepatitis B. China J Modern Med. 2004; 14: 54-6.

Fickenscher H, Hör S, Küpers H, Knappe A, Wittmann S, Sticht H. The interleukin-10 family of cytokines. Trends Imunol. 2002; 23(2): 89-96, CrossRef.

Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, et al. A study of circulating interleukin-10 in prognosticatication of unresectable hepatocellular carcinoma. Cancer. 2012; 118: 3984-92, CrossRef.

Rybicka M, Woziwodzka A, Sznarkowska A, Romanowski T, Stalke P, Dręczewski M, et al. Genetic variation in IL-10 influences the progression of hepatitis B infection. Int J Infect Dis. 2020; 96: 260-5, CrossRef.

Saxena R, Chawla YK, Verma I, Kaur J. Association of interleukin-10 with hepatitis B virus (HBV) mediated disease progression in Indian population. Indian J Med Res. 2014; 139(5): 737-45, PMID.

Wu JF, Wu TC, Chen CH, Ni YH, Chen HL, Hsu HY, et al. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology. 2010; 138(1): 165-72.e1-3, CrossRef.

Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol. 2011; 55(4): 762-9, CrossRef.

Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest. 1997; 99(12): 3025-33, CrossRef.

Hsieh HG, Huang HC, Lee FY, Chan CY, Lee JY, Lee SD. Kinetics of cytokine expression in cirrhotic rats. J Chin Med Assoc. 2011; 74(9): 385-93, CrossRef.

Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. CMAJ. 2005; 172(3): 367-79, CrossRef.

Tacke F, Hammerich L, Heymann F. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol. 2011; 2011: 345803, CrossRef.

Trehanpati N, Vyas AK. Immune regulation by T regulatory cells in hepatitis B virus-related inflammation and cancer. Scand J Immunol 2017; 85(3): 175-81, CrossRef.

Monastero RN, Pentyala S. Cytokines as biomarkers and their respective clinical cutoff levels. Int J Inflam. 2017: 2017: 4309485, CrossRef.


Copyright (c) 2024 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Indexed by:






The Prodia Education and Research Institute